Thésaurus cancer du poumon - GOThA (Groupe d'Oncologie ...

28. Pujol Vancoover 2003
29. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S. Duration of
chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin,
vinblastine, and cisplatin. J Clin Oncol. 2001 Mar 1;19(5):1336-43.
30. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies
MS. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in
advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002 Mar 1;20(5):1335-43.
31. Andresen O. Duration of chemotherapy and survival in advanced non-small-cell lung cancer. A muliticenter prospective
randomised study. advanced non-small-cell lung cancer. 10 World conference on lung cancer. Lung cancer 2003;41(2):S28.
32. DepierreA. Maintenance chemotherapy in advanced non-small cell lung cancer: a randomized study of vinorelbine versus
observations in patients responding to induction theapy. Proc Am Soc Clin Oncol 2001;20:309a.
33. Krakowski M. Gemcitabine and cisplatine +/- maintenance therapy with single-agent gemcitabine in advanced non-small-cell
lung cancer. Preliminary results of a randomized trial of the Central European Cooperative Oncology Group.10 World
conference on lung cancer. Lung cancer 2003;41(2):S29.
34. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH. Cisplatin-based therapy for elderly
patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized
trial. J Natl Cancer Inst. 2002 Feb 6;94(3):173-81.
35. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M,
Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G,
Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell
lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer
Inst. 2003 Mar 5;95(5):362-72.
36. Langer CJ. Elderly patients with lung cancer: biases and evidence. Curr Treat Options Oncol. 2002 Feb;3(1):85-102. Review.
37. Lilenbaum RC, Herndon J, List M et al. Single agent versus combinaison chemotherapy in advanced non-small cell lung
cancer : a CALGB randomized trial of efficacity, quality of life and cost-effictiveness. ProcASCO 2002;21:A2.
38. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R,
Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell
lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095-103.
39. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara
D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus
vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing
chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun;18(12):2354-62.
Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209.
40. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated
with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97.
7. LES THERAPEUTIQUES CIBLEES
Parmi toutes les différentes thérapeutiques ciblées à l’essai dans les cancers bronchiques seuls deux
inhibiteurs du site tyrosine kinase du récepteur de l’EGFR ont fait l’objet d’essais contrôlés : Le ZD
1839 (gefitinib, Iressa ®) et l’ OSI 774 (erlotinib, Tarceva ®).
Ces deux molécules ont été testées en première ligne en association avec une chimiothérapie
conventionnelle et en monothérapie après échec d’une chimiothérapie conventionnelle.
7. 1 - Première ligne thérapeutique en association avec une chimiothérapie conventionnelle.
Les deux molécules ont été testées dans des essais randomisés contre placebo, associés à des doublets
de chimiothérapie identique (Cisplatine – Gemcitabine et Carboplatine -Taxol) chez des patients
atteints de CNPC de stade III ou IV et non pré-traités. Ces essais (INTACT 1 et 2 pour l’Iressa ®,
TALENT et TRIBUTE pour le Tarceva ®) sont négatifs.
09/10/2006 53